Search results
Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) largest shareholders are private equity firms with 48%...
Simply Wall St. via Yahoo Finance· 5 months agoKey Insights Lexicon Pharmaceuticals' significant private equity firms ownership suggests that the...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own...
Simply Wall St. via Yahoo Finance· 10 months agoKey Insights Significant control over Lexicon Pharmaceuticals by private equity firms implies that...
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out...
Zacks via Yahoo Finance· 3 months agoLexicon (LXRX) doesn't possess the right combination of the two key ingredients for a likely...
Lexicon Pharmaceuticals Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St. via Yahoo Finance· 2 years agoLexicon Pharmaceuticals (NASDAQ:LXRX) Third Quarter 2022 ResultsKey Financial Results Net loss:...
Lexicon's (LXRX) Heart Failure Drug Inpefa Gets FDA Approval
Zacks via Yahoo Finance· 1 year agoLexicon’s LXRX shares were up almost 18% on May 26, after market hours. The rise was due to the FDA...
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 1 month agoLexicon (LXRX) delivered earnings and revenue surprises of -11.11% and 3.09%, respectively, for the...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 7 months agoLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript November 8, 2023...
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
Zacks via Yahoo Finance· 3 months agoNew post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic...
Independent Chairman of the Board of Lexicon Pharmaceuticals Picks Up 293% More Stock
Simply Wall St. via Yahoo Finance· 8 months agoThose following along with Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will no doubt be intrigued by...
Lexicon Pharma's Pain Candidate Fails In Postherpetic Neuralgia Study
Benzinga via Yahoo Finance· 1 year agoLexicon Pharmaceuticals Inc (NASDAQ: LXRX) announced the topline results of RELIEF-PHN-1 Phase 2...